Egyszerű nézet Goette A Merino JL Ezekowitz MD Zamoryakhin D Melino M Jin J Mercuri MF Grosso MA Fernandez V Al-Saady N Pelekh N Merkely, Béla Péter Zenin S Kushnir M Spinar J Batushkin V de Groot JR Lip GY ENSURE-AF investigators 2018-08-09T13:23:38Z 2018-08-09T13:23:38Z 2016
dc.identifier 84992105111
dc.identifier.citation pagination=1995-2003; journalVolume=388; journalIssueNumber=10055; journalTitle=LANCET;
dc.identifier.uri doi:10.1016/S0140-6736(16)31474-X
dc.description.abstract BACKGROUND: Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy. Few safety data about edoxaban in patients undergoing electrical cardioversion are available. METHODS: We did a multicentre, prospective, randomised, open-label, blinded-endpoint evaluation trial in 19 countries with 239 sites comparing edoxaban 60 mg per day with enoxaparin-warfarin in patients undergoing electrical cardioversion of non-valvular atrial fibrillation. The dose of edoxaban was reduced to 30 mg per day if one or more factors (creatinine clearance 15-50 mL/min, low bodyweight [</=60 kg], or concomitant use of P-glycoprotein inhibitors) were present. Block randomisation (block size four)-stratified by cardioversion approach (transoesophageal echocardiography [TEE] or not), anticoagulant experience, selected edoxaban dose, and region-was done through a voice-web system. The primary efficacy endpoint was a composite of stroke, systemic embolic event, myocardial infarction, and cardiovascular mortality, analysed by intention to treat. The primary safety endpoint was major and clinically relevant non-major (CRNM) bleeding in patients who received at least one dose of study drug. Follow-up was 28 days on study drug after cardioversion plus 30 days to assess safety. This trial is registered with, number NCT02072434. FINDINGS: Between March 25, 2014, and Oct 28, 2015, 2199 patients were enrolled and randomly assigned to receive edoxaban (n=1095) or enoxaparin-warfarin (n=1104). The mean age was 64 years (SD 10.54) and mean CHA2DS2-VASc score was 2.6 (SD 1.4). Mean time in therapeutic range on warfarin was 70.8% (SD 27.4). The primary efficacy endpoint occurred in five (<1%) patients in the edoxaban group versus 11 (1%) in the enoxaparin-warfarin group (odds ratio [OR] 0.46, 95% CI 0.12-1.43). The primary safety endpoint occurred in 16 (1%) of 1067 patients given edoxaban versus 11 (1%) of 1082 patients given enoxaparin-warfarin (OR 1.48, 95% CI 0.64-3.55). The results were independent of the TEE-guided strategy and anticoagulation status. INTERPRETATION: ENSURE-AF is the largest prospective randomised clinical trial of anticoagulation for cardioversion of patients with non-valvular atrial fibrillation. Rates of major and CRNM bleeding and thromboembolism were low in the two treatment groups. FUNDING: Daiichi Sankyo provided financial support for the study.
dc.relation.ispartof urn:issn:0140-6736
dc.title Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
dc.type Journal Article 2018-07-13T07:40:32Z
dc.language.rfc3066 en
dc.identifier.mtmt 3132594
dc.identifier.pubmed 27590218
dc.contributor.department SE/AOK/K/Városmajori Szív- és Érgyógyászati Klinika
dc.contributor.department SE/AOK/K/VAROSMAJOR_SZÍVÉRGYÓGY/Kardiológia Központ - Kardiológiai Tanszék [2017.10.31]
dc.contributor.institution Semmelweis Egyetem

Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.


Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet